RCUS (Arcus Biosciences) Moat Score: 5/10 (As of Jun. 28, 2026)


RCUS Arcus Biosciences Inc RCUS
46 GF Score
Price $31.00
GF Value $13.76
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Arcus Biosciences Moat Score?

Arcus Biosciences RCUS +2.48% 46 Moat Score is 5 as of Jun. 28, 2026. GuruFocus rates RCUS with a GF Score™ of 46/100 and a GF Value™ of $13.76 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,402 Biotechnology companies, Arcus Biosciences ranks better than 96.72% on this metric.

Arcus Biosciences has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Arcus Biosciences has Narrow Moat: Arcus Biosciences has a solid narrow moat due to its valuable intellectual property and R&D capabilities in the biotech sector. While it has potential for strong innovation, it faces intense competition and lacks significant market leadership or pricing power.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Arcus Biosciences might have Narrow Moat - Solid narrow moat.

Arcus Biosciences  (NYSE:RCUS) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Arcus Biosciences Moat Score Related Terms

RCUS vs TNGX, DYN, RLAY: Moat Score Comparison

For the Biotechnology subindustry, Arcus Biosciences's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arcus Biosciences Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arcus Biosciences's Moat Score distribution charts can be found below:

* The bar in red indicates where Arcus Biosciences's Moat Score falls into.


RCUS
46GF Score
Arcus Biosciences Inc RCUS
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Arcus Biosciences (RCUS) has a Moat Score of 5 as of Jun. 28, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Arcus Biosciences ranks #46 out of 1402 companies in the Biotechnology industry, placing it in the top 3.3%.
Is Arcus Biosciences' Moat Score too high?
Arcus Biosciences' current Moat Score is 5. The Biotechnology industry median Moat Score is 2.00. Arcus Biosciences' value of 5 is 150% above this industry median. Based on the distribution chart, Arcus Biosciences ranks #46 out of 1402 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Arcus Biosciences has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arcus Biosciences' Moat Score compare to TNGX and DYN?
According to the Biotechnology industry distribution chart, Arcus Biosciences ranks #46 out of 1402 companies for Moat Score. This places Arcus Biosciences in the top 3% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Arcus Biosciences' value of 5 is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,402 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arcus Biosciences's current Moat Score of 5 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arcus Biosciences's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcus Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Arcus Biosciences (RCUS) is currently considered Significantly Overvalued. The stock's GF Value™ is $13.76, compared to a current price of $31.00 — trading 125.3% above its estimated fair value. The current Moat Score is 5 and 150% above the Biotechnology industry median of 2.00. Arcus Biosciences' overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Arcus Biosciences (RCUS), the current Moat Score is 5 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arcus Biosciences (RCUS) Overvalued in 2026?

Based on GuruFocus' analysis, Arcus Biosciences stock appears to be overvalued. The current stock price of $31.00 is trading 125.3% above its estimated GF Value™ of $13.76. GuruFocus considers Arcus Biosciences to be Significantly Overvalued.

Key valuation signals for RCUS:

  • Moat Score: 5
  • GF Value™: $13.76 vs. price of $31.00 (125.3% above fair value)
  • GF Score™: 46/100 with 6 warning signs
  • Industry Position: 150% above the Biotechnology median (#46 of 1402)

No single metric tells the full story. See the RCUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arcus Biosciences Business Description

Address 3928 Point Eden Way, Hayward, CA, USA, 94545
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
46GF Score

Get the complete analysis for RCUS

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.00
Price
$13.76
GF Value